You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Is labetalol really a culprit in neonatal hypoglycaemia?
  1. Nikolaos Daskas1,
  2. Elizabeth Crowne1,
  3. Julian PH Shield2
  1. 1Department of Paediatric Endocrinology and Diabetes, Bristol Royal Hospital for Children, Bristol, UK
  2. 2Department of Child Health, University of Bristol, Bristol, UK
  1. Correspondence to Dr Nikolaos Daskas, Department of Paediatric Endocrinology and Diabetes, Level 6 Education Centre, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol BS2 8BJ, UK; nikolaos.daskas{at}uhbristol.nhs.uk

https://doi.org/10.1136/archdischild-2012-303057

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A recent publication from the UNICEF baby friendly initiative1 particularly identifies ‘use of maternal beta-blockers such as Labetalol’ as a risk factor for neonatal hypoglycaemia. Labetalol is a combined α- and β-adrenoreceptor that decreases peripheral vascular resistance without significant alteration of heart rate or cardiac output. It has been used to treat pregnancy-induced hypertension and although there have been isolated reports of neonatal hypoglycaemia in association with maternal labetalol treatment, these …

    View Full Text

    Footnotes

    • Contributors JPH-S conceived the idea for the letter, contributed to the literature search, served as the scientific advisor with EC and approved the final version of the letter to publish. ND performed the literature search, wrote the letter and is the guarantor. All contributors critically reviewed the referenced articles.

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.